Search research articles
Contact Us
Filters
Showing results (41-50 of 81) with videos related to
Page
of 9
Sort By:
Cancers
|
September 27, 2025
First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms
Simone Thomas, Martin Wermke, Vladan Vučinić, et al.
Cancer Management and Research
|
February 25, 2022
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
Katja Sockel, Friedrich Stölzel, Franziska Hönl, et al.
British Journal of Haematology
|
October 8, 2016
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)
Martin Wermke, Claudia Schuster, Florian Nolte, et al.
The Lancet. Haematology
|
April 10, 2018
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial
Martin Wermke, Julia Eckoldt, Katharina S Götze, et al.
Clinical Lung Cancer
|
April 29, 2026
A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations
Cornelia Kropf-Sanchen, Nikolaj Frost, Jonas Kuon, et al.
Frontiers in Immunology
|
October 31, 2022
Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease
Thomas Krüger, Rebekka Wehner, Maik Herbig, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer
David Planchard, Jürgen Wolf, Benjamin Solomon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
Theresa Medina, Jason A Chesney, Harriet M Kluger, et al.
British Journal of Haematology
|
April 9, 2024
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study
Christoph Röllig, Christoph Schliemann, Leo Ruhnke, et al.
Cancer Immunology, Immunotherapy : CII
|
June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
Jan Budczies, Martina Kirchner, Klaus Kluck, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 81) with videos related to
Sort By:
Page
of 9
Cancers
|
September 27, 2025
First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms
Simone Thomas, Martin Wermke, Vladan Vučinić, et al.
Cancer Management and Research
|
February 25, 2022
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
Katja Sockel, Friedrich Stölzel, Franziska Hönl, et al.
British Journal of Haematology
|
October 8, 2016
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)
Martin Wermke, Claudia Schuster, Florian Nolte, et al.
The Lancet. Haematology
|
April 10, 2018
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial
Martin Wermke, Julia Eckoldt, Katharina S Götze, et al.
Clinical Lung Cancer
|
April 29, 2026
A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations
Cornelia Kropf-Sanchen, Nikolaj Frost, Jonas Kuon, et al.
Frontiers in Immunology
|
October 31, 2022
Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease
Thomas Krüger, Rebekka Wehner, Maik Herbig, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer
David Planchard, Jürgen Wolf, Benjamin Solomon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study
Theresa Medina, Jason A Chesney, Harriet M Kluger, et al.
British Journal of Haematology
|
April 9, 2024
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study
Christoph Röllig, Christoph Schliemann, Leo Ruhnke, et al.
Cancer Immunology, Immunotherapy : CII
|
June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
Jan Budczies, Martina Kirchner, Klaus Kluck, et al.
Page
of 9